✦ LIBER ✦

The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis

✍ Scribed by Alessandra Battaglia; Andrea Fattorossi; Luca Pierelli; Giuseppina Bonanno; Maria Marone; Franco O. Ranelletti; Annamaria Coscarella; Rita De Santis; Simona Bach; Salvatore Mancuso; Giovanni Scambia

Book ID: 114216114
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 622 KB
Volume: 28
Category: Article
ISSN: 0301-472X
DOI: 10.1016/s0301-472x(00)00136-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expansion of granulocyte colony–stimulat

Expansion of granulocyte colony–stimulating factor/chemotherapy–mobilized CD34+ hematopoietic progenitors: Role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15

✍ Luca Pierelli; Giovanni Scambia; Giuseppina Bonanno; Annamaria Coscarella; Rita 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 398 KB

Expression of the fusion protein recombi

Expression of the fusion protein recombinant human granulocyte-macrophage colony stimulating factor and leukemia inhibitory factor in a baculovirus vector system

✍ X-W Zhang; X-Y Zeng; T Sun; X Liu; D-X Gu 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 51 KB

Effect of active immunization against a

Effect of active immunization against a recombinant mouse granulocyte-macrophage colony-stimulating factor/somatostatin fusion protein on the growth of mice

✍ Bingbing Wu; Ruili Qi; Bin Li; Taoyan Yuan; Heshan Liu; Jun He; Zhiwei Lin; Weif 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 319 KB

Characterization of the microheterogenei

Characterization of the microheterogeneities of PIXY321, a genetically engineered granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein expressed in yeast

✍ Alain Balland; Dace A. Krasts; Kayt L. Hoch; Mary J. Gerhart; Kay E. Stremler; S 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 3 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a